CRMD
CorMedix Inc
NASDAQ: CRMD · HEALTHCARE · BIOTECHNOLOGY
$7.51
-2.11% today
Updated 2026-06-05
Market cap
$669.98M
P/E ratio
3.94
P/S ratio
1.61x
EPS (TTM)
$2.17
Dividend yield
—
52W range
$6 – $17
Volume
1.2M
WallStSmart proprietary scores
80
out of 100
Grade: A
Strong Buy
Investment rating
8.3
Growth
A6.5
Quality
B10.0
Profitability
A+6.7
Valuation
B3/9
Piotroski F-Score
Weak
1.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$15.33
+104.13%
12-Month target
$5.29
-29.56%
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 45.30% — above average
+ ROE 41.42% — strong efficiency
+ Free cash flow $41.65M — positive
+ Revenue growth 226.10% QoQ
+ Debt/equity 0.33x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z 1.54 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $65408.00 | $0.00 | $43.47M | $311.71M | $400.05M |
| Net income | $-29.70M | $-46.34M | $-17.93M | $163.06M | $38.60M |
| EPS | — | — | — | — | $2.17 |
| Free cash flow | $-24.58M | $-38.74M | $-50.73M | $172.79M | $41.65M |
| Profit margin | -45,409.90% | — | -41.24% | 52.31% | 45.30% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-04 | ZELNICK, KAUFMAN BETH | Buy | 36,006 | — |
| 2026-02-04 | TODISCO, JOSEPH | Buy | 77,156 | — |
| 2026-02-04 | HURLBURT, ELIZABETH | Buy | 36,006 | — |
Peer comparison
Smart narrative
CorMedix Inc trades at $7.51. representing a P/E of 3.94x trailing earnings. Our Smart Value Score of 80/100 indicates the stock is excellent. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.54, it sits in the distress. TTM revenue stands at $400.05M. with profit margins at 45.30%.
Frequently asked questions
What is CorMedix Inc's stock price?
CorMedix Inc (CRMD) trades at $7.51, on a P/E of 3.9x and a P/S of 1.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is CorMedix Inc overvalued?
CorMedix Inc carries a Smart Value Score of 80/100 (Grade A), which we rate Strong Buy. That score blends growth, quality, and valuation into one read.
What is the price target of CorMedix Inc (CRMD)?
The 12-month analyst consensus target is $15.33, about 104.1% above the current $7.51. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of CRMD by 2030?
Our research-backed model puts the 2030 base case at $13.86, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is CorMedix Inc's revenue?
CorMedix Inc's trailing twelve-month revenue is $400.05M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
CorMedix Inc's Altman Z-Score is 1.54, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.61x
ROE41.42%
Beta1.47
50D MA$7.55
200D MA$9.45
Shares out0.08B
Float0.07B
Short ratio—
Avg volume1.2M
Performance
1 week+0.00%
1 month+10.73%
3 months+27.83%
YTD-28.12%
1 year—
3 years—
5 years—